Combination of a novel oncolytic immunotherapeutic agent, CAVATAK (coxsackievirus A21) and immune-checkpoint blockade significantly reduces tumor growth and improves survival in an...

por Shafren, Darren, Quah, Min, Wong, Yvonne, Andtbacka, Robert HI, Kaufman, Howard L, Au, Gough G
Publicado 2014

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase I...

por Harrington, Kevin J, Andtbacka, Robert HI, Collichio, Frances, Downey, Gerald, Chen, Lisa, Szabo, Zsolt, Kaufman, Howard L
Publicado 2016

Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase II...

por Kaufman, Howard L, Andtbacka, Robert HI, Collichio, Frances A, Wolf, Michael, Li, Ai, Shilkrut, Mark, Puzanov, Igor, Ross, Merrick
Publicado 2014

Phase II calm extension study: Coxsackievirus A21 delivered intratumorally to patients with advanced melanoma induces immune-cell infiltration in the tumor microenvironment

por Andtbacka, Robert HI, Curti, Brendan D, Hallmeyer, Sigrun, Feng, Zipei, Paustian, Christopher, Bifulco, Carlo, Fox, Bernard, Grose, Mark, Shafren, Darren
Publicado 2015

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma

por Andtbacka, Robert H.I., Amatruda, Thomas, Nemunaitis, John, Zager, Jonathan S., Walker, John, Chesney, Jason A., Liu, Kate, Hsu, Cheng-Pang, Pickett, Cheryl A., Mehnert, Janice M.
Publicado 2019

Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melan...

por Andtbacka, Robert HI, Collichio, Frances A, Amatruda, Thomas, Senzer, Neil, Chesney, Jason, Delman, Keith, Spitler, Lynn, Puzanov, Igor, Agarwala, Sanjiv, Milhem, Mohammed, Harrington, Kevin, Middleton, Mark, Li, Ai, Shilkrut, Mark, Coffin, Robert, Kaufman, Howard
Publicado 2014

Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma

por Andtbacka, Robert H.I., Wang, Yan, Pierce, Robert H., Campbell, Jean S., Yushak, Melinda, Milhem, Mohammed, Ross, Merrick, Niland, Katie, Arbeit, Robert D., Parasuraman, Sudha, Bickley, Kris, Yeung, Cecilia CS, Aicher, Lauri D., Smythe, Kimberly S., Gan, Lu
Publicado 2022

A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma

por Ray, Abhijit, Williams, Matthew A., Meek, Stephanie M., Bowen, Randy C., Grossmann, Kenneth F., Andtbacka, Robert H.I., Bowles, Tawnya L., Hyngstrom, John R., Leachman, Sancy A., Grossman, Douglas, Bowen, Glen M., Holmen, Sheri L., VanBrocklin, Matthew W., Suneja, Gita, Khong, Hung T.
Publicado 2016

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKE...

por Long, Georgina V, Dummer, Reinhard, Ribas, Antoni, Puzanov, Igor, Michielin, Olivier, VanderWalde, Ari, Andtbacka, Robert HI, Cebon, Jonathan, Fernandez, Eugenio, Malvehy, Josep, Olszanski, Anthony J, Gajewski, Thomas F, Kirkwood, John M, Kuznetsova, Olga, Chen, Lisa, Kaufman, David R, Chou, Jeffrey, Hodi, F Stephen
Publicado 2015

BRAF(V600E) induces reversible mitotic arrest in human melanocytes via microRNA-mediated suppression of AURKB

por McNeal, Andrew S, Belote, Rachel L, Zeng, Hanlin, Urquijo, Marcus, Barker, Kendra, Torres, Rodrigo, Curtin, Meghan, Shain, A Hunter, Andtbacka, Robert HI, Holmen, Sheri, Lum, David H, McCalmont, Timothy H, VanBrocklin, Matt W, Grossman, Douglas, Wei, Maria L, Lang, Ursula E, Judson-Torres, Robert L
Publicado 2021